<DOC>
	<DOCNO>NCT00850304</DOCNO>
	<brief_summary>Our purpose study explore feasibility treatment non promyelocytic Acute myeloid leukaemia elderly patient . We select ten patient age 60 comorbidity treat low dose cytosar subcutaneous plus arsenic trioxide ten day month . We assess overall response rate overall survival end one year .</brief_summary>
	<brief_title>Treatment Non Promyelocytic Acute Myeloid Leukaemia Elderly Patients Low Dose Cytosar Plus Arsenic Trioxide</brief_title>
	<detailed_description>Acute myeloid leukemia disease characterise blast 20 % bone marrow plus incomplete differentiation . Many patient elderly age 60 year ( CALGB , ECOG , EORTC ) 55 year ( SWOG ) . Mortality rate fallowing standard therapy patient high reach 50 % . One method apply remission least mortality morbidity also significant low cost effect compare historical conventional standard regimen low dose cytosar arsenic trioxide combination report complete remission 34 % . We select ten patient age 60 comorbidity treat low dose cytosar subcutaneous plus arsenic trioxide ten day month . We assess overall response rate overall survival end one year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Elderly patient non promyelocytic AML Performance status ( ECOG ) 3 4 Age &lt; 60 year Elevation AST OR ALT ten time normal Serum bilirubin 5 Cr level &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>AML</keyword>
</DOC>